Compare VanEck Gold Miners ETF (GDX) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Globus Medical Inc. Class A Common Stock — how do they compare? VanEck Gold Miners ETF trades at $85.04 (market cap $26.33B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: VanEck Gold Miners ETF is far larger — about 2.6× Globus Medical Inc. Class A Common Stock's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 77 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| GDX | GMED | |
|---|---|---|
Market Cap | $26.33B | $10.25B |
Volume | 31,283,423 | 1,059,528 |
52-Week High | $115.84 | $96.82 |
52-Week Low | $68.28 | $58.33 |
Typical Hold Time | 77 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $87.24, down 1.46% over the past day, with a neutral technical signal and bearish moving averages. Key support is at $87, with resistance at $89. Financial ratios are unavailable, but recent news highlights institutional selling and comparisons between gold miners and physical gold ETFs. The fund's performance is influenced by gold prices and interest rate trends.
Outlook remains mixed amid gold price volatility and rising rates. Opportunities include potential catch-up if gold rallies, but risks involve further institutional outflows and macroeconomic pressure on metals. Investor sentiment is cautious, with technicals suggesting limited near-term momentum.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
